Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

NCT03628131 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03628131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03628131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
Lead sponsor
Samsung Medical Center
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2018
Completion date
July 31, 2025
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory pediatric solid tumor, relapsed pediatric solid tumor